TBPH
Theravance Biopharma Inc
NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY
$16.52
-2.88% today
Updated 2026-05-11
Market cap
$876.78M
P/E ratio
7.63
P/S ratio
7.99x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$8 – $21
Volume
0.6M
Theravance Biopharma Inc (TBPH) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.85M | $130.15M | $226000.00 | $11.69M | $42.13M | $48.65M | $15.39M | $60.37M | $73.41M | $71.86M | $55.31M | $51.35M | $57.42M | $64.38M | $107.46M |
| Revenue growth (YoY) | — | +776.2% | -99.8% | +5071.7% | +260.4% | +15.5% | -68.4% | +292.4% | +21.6% | -2.1% | -23.0% | -7.2% | +11.8% | +12.1% | +66.9% |
| Cost of revenue | $3.84M | $114.00M | $120.58M | $4.06M | $4.66M | $2.89M | $6.03M | $715000.00 | $219.25M | $260.95M | $193.66M | $63.39M | $40.62M | $6.01M | $5.51M |
| Gross profit | $11.01M | $16.15M | $-120.35M | $7.63M | $37.47M | $45.75M | $9.36M | $59.66M | $73.41M | $71.86M | $-138.35M | $-12.05M | $16.80M | $64.38M | $101.95M |
| Gross margin | 74.1% | 12.4% | -53253.5% | 65.3% | 88.9% | 94.1% | 60.8% | 98.8% | 100.0% | 100.0% | -250.1% | -23.5% | 29.3% | 100.0% | 94.9% |
| R&D | $98.85M | $114.00M | $120.58M | $168.52M | $129.16M | $141.71M | $173.89M | $201.35M | $219.25M | $260.95M | $201.55M | $70.07M | $46.34M | $37.64M | $37.41M |
| SG&A | — | — | $35.93M | $71.65M | $90.20M | $84.51M | $95.59M | $97.06M | $106.08M | $108.66M | $99.30M | $59.07M | $65.35M | $64.87M | $73.65M |
| Operating income | $-109.33M | $-9.57M | $-156.28M | $-232.54M | $-181.90M | $-180.47M | $-260.12M | $-238.75M | $-251.91M | $-297.63M | $-257.78M | $-91.96M | $-56.03M | $-46.95M | $-13.25M |
| Operating margin | -736.1% | -7.4% | -69152.2% | -1989.6% | -431.8% | -371.0% | -1690.6% | -395.5% | -343.1% | -414.2% | -466.1% | -179.1% | -97.6% | -72.9% | -12.3% |
| EBITDA | $-105.49M | $-6.32M | $-153.63M | $-229.88M | $-178.77M | $-176.04M | $-259.14M | $-212.44M | $-203.60M | $-287.82M | $-232.83M | $-76.08M | $-51.65M | $-38.45M | $-7.73M |
| EBITDA margin | -710.2% | -4.9% | -67978.3% | -1966.8% | -424.4% | -361.9% | -1684.2% | -351.9% | -277.3% | -400.6% | -420.9% | -148.2% | -89.9% | -59.7% | -7.2% |
| EBIT | $-109.33M | $-9.57M | $-156.28M | $-232.54M | $-181.76M | $-179.16M | $-263.16M | $-215.60M | $-209.81M | $-294.80M | $-237.64M | $-79.12M | $-53.65M | $-42.07M | $-13.25M |
| Interest expense | — | $0.00 | $0.00 | $1.86M | $631000.00 | $1.40M | $8.55M | $10.48M | $31.86M | $8.55M | $8.55M | $6.37M | $2.35M | $2.55M | $2.46M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-109.33M | $-9.57M | $-156.28M | $-237.04M | $-182.22M | $-190.67M | $-285.40M | $-215.52M | $-236.46M | $-278.02M | $-199.43M | $872.13M | $-55.19M | $-56.42M | $105.89M |
| Net income growth (YoY) | — | +91.2% | -1532.2% | -51.7% | +23.1% | -4.6% | -49.7% | +24.5% | -9.7% | -17.6% | +28.3% | +537.3% | -106.3% | -2.2% | +287.7% |
| Profit margin | -736.1% | -7.4% | -69152.2% | -2028.0% | -432.6% | -391.9% | -1855.0% | -357.0% | -322.1% | -386.9% | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |